Roy Gulick, M.D., M.P.H., discusses the results of his two-year study on treatment-experienced patients taking vicriviroc (SCH 417690, SCH-D), a CCR5 inhibitor in development.

Joel Gallant, M.D., M.P.H., wraps up our daily recap series from the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention with a wide-ranging discussion of important studies on first-line therapy, therapy options for treatment-experienced patients, antiretrovirals in development, abacavir hypersensitivity testing and the metabolic impact of antiretroviral switching.

Calvin J. Cohen, M.D., M.S., discusses the role of new agents in suppressing HIV.

Eric Daar, M.D., discusses what he considers to be the two big studies of IAS 2007, the ongoing debate about when-to-start treatment, and his own take on circumcision as prevention in the developed world.

Pietro Vernazza, M.D., offers his take on the when-to-start HIV treatment debate, circumcision and cardiovascular complications.

Edwin DeJesus, M.D., F.A.C.P., discusses data supporting the possibility that at least some cross-resistance occurs between the integrase inhibitors in development: elvitegravir (GS 9137) and raltegravir (MK-0518).

Benoit Marin discusses the association between CD4+ count and viral load and death due to non-AIDS causes.

Annette Sohn, M.D., summarizes her plenary presentation on pediatric treatment issues and answers questions about global pediatric HIV.

Jonathan Uy, M.D., discusses how the initiation of HAART at a CD4+ cell count of 350 cells/mm3 is associated with a lower prevalence of antiretroviral resistance mutations at virologic failure.

Pietro Vernazza, M.D., discusses his poster on pre-exposure prophylaxis and timed unprotected intercourse for HIV-discordant heterosexual couples wanting to conceive a child.